EP1546714A4 - Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer - Google Patents
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancerInfo
- Publication number
- EP1546714A4 EP1546714A4 EP02799873A EP02799873A EP1546714A4 EP 1546714 A4 EP1546714 A4 EP 1546714A4 EP 02799873 A EP02799873 A EP 02799873A EP 02799873 A EP02799873 A EP 02799873A EP 1546714 A4 EP1546714 A4 EP 1546714A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- diagnosis
- therapy
- compositions
- methods
- human cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
WOPCT/US02/27836 | 2002-08-30 | ||
PCT/US2002/027836 WO2003022991A2 (en) | 2001-09-07 | 2002-08-30 | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
PCT/US2002/034987 WO2004020999A1 (en) | 2002-08-30 | 2002-10-30 | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1546714A1 EP1546714A1 (en) | 2005-06-29 |
EP1546714A4 true EP1546714A4 (en) | 2007-12-05 |
Family
ID=31975571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02799873A Withdrawn EP1546714A4 (en) | 2002-08-30 | 2002-10-30 | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1546714A4 (en) |
AU (1) | AU2002364501A1 (en) |
CA (1) | CA2496938A1 (en) |
WO (1) | WO2004020999A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1521776A2 (en) | 2002-07-04 | 2005-04-13 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
DE10311248A1 (en) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody |
EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
DE10353175A1 (en) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Human monoclonal antibody with fatliquoring effect |
US20050191294A1 (en) * | 2003-12-31 | 2005-09-01 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
BRPI0710671B8 (en) * | 2006-04-07 | 2021-05-25 | Univ Texas | use of a therapeutic adeno-associated viral bacteriophage vector (aavp) for the manufacture of a drug for the treatment and prophylaxis of a hyperproliferative disease |
JP5374360B2 (en) * | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient |
US20110189095A1 (en) * | 2008-06-20 | 2011-08-04 | The Board Of Regents, Of The University Of Texas System | Crkl targeting peptides |
CN102120755B (en) * | 2010-04-23 | 2013-04-03 | 江苏省人民医院 | Brown adipose tissue targeted polypeptide and applications thereof |
CN113278731A (en) * | 2021-05-12 | 2021-08-20 | 广西医科大学 | lncRNA marker for judging antiviral treatment effect of HIV-1 infected person and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020724A2 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Adenoviral targeting and manipulation of immune system response using targeting peptides |
WO2002020769A1 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Human and mouse targeting peptides identified by phage display |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) * | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
ATE229073T1 (en) * | 1996-09-06 | 2002-12-15 | Univ California | PROTEIN E25A, METHODS OF ITS PRODUCTION AND APPLICATION |
US6261789B1 (en) * | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Methods for detecting the presence of a PSCA protein using PSCA antibodies |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
-
2002
- 2002-10-30 CA CA002496938A patent/CA2496938A1/en not_active Abandoned
- 2002-10-30 WO PCT/US2002/034987 patent/WO2004020999A1/en not_active Application Discontinuation
- 2002-10-30 EP EP02799873A patent/EP1546714A4/en not_active Withdrawn
- 2002-10-30 AU AU2002364501A patent/AU2002364501A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020724A2 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Adenoviral targeting and manipulation of immune system response using targeting peptides |
WO2002020769A1 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Human and mouse targeting peptides identified by phage display |
WO2002020722A2 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas Syste | Methods and compositions for in vitro targeting |
WO2002020723A2 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Compositions and methods for targeting peptides in humans in vivo |
WO2002020822A2 (en) * | 2000-09-08 | 2002-03-14 | Board Of Regents, The University Of Texas System | Biopanning and rapid analysis of selective interactive ligands (brasil) |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004020999A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1546714A1 (en) | 2005-06-29 |
WO2004020999A1 (en) | 2004-03-11 |
AU2002364501A1 (en) | 2004-03-19 |
CA2496938A1 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003302892A8 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
EP1571968A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1589933A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1478276A4 (en) | Novel targeted compositions for diagnostic and therapeutic use | |
EP1515982A4 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
EP1572091A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1578996A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1553912A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1551990A4 (en) | Diagnosis and treatment of chemoresistant tumors | |
EP1575571A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1516049A4 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
EP1539251A4 (en) | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis | |
EP1446013A4 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
ZA200510282B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1546714A4 (en) | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer | |
EP1532162A4 (en) | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors | |
EP1420814A4 (en) | Compositions and methods for the therapy and diagnosis of breast cancer | |
AU2003237792A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2003246592A1 (en) | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases | |
AU2003230849A8 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
AU2003250912A8 (en) | Agents and methods for diagnosis and therapy of cancer and cancer risk assessment | |
GB0326578D0 (en) | Cancer diagnosis and therapy | |
AU2003260301A8 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
AU2003245858A8 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
AU2003279312A8 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050323 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20071105 |
|
17Q | First examination report despatched |
Effective date: 20080514 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080925 |